Evidence map›Paper›PMID 29056882›Full record

ArticleCurrent sexual health reports2017

Effects of Testosterone on Benign and Malignant Conditions of the Prostate.

Amin S Herati, Taylor P Kohn, Peter R Butler, Larry I Lipshultz

Abstract read
In one paragraph

Article in Current sexual health reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Androgen action in prostate function and disease.American journal of clinical and experimental urology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Amin S HeratiCenter for Reproductive Medicine, Baylor College of Medicine, Houston, TX 77030.
Taylor P KohnScott Department of Urology, Baylor College of Medicine, Houston, TX 77030.
Peter R ButlerCenter for Reproductive Medicine, Baylor College of Medicine, Houston, TX 77030.
Larry I LipshultzCenter for Reproductive Medicine, Baylor College of Medicine, Houston, TX 77030.
Baylor College of Medicine · US

Funding

K-12: Male Reproductive Health Research (MRHR) Career Development Program at BCMK12HD073917 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI LAMB, DOLORES JEAN · 2012 to 2016
$1.7M
NICHD NIH HHS K12 HD073917
6 · The paper itself

Abstract

purpose of the reviewThis review summarizes the current literature regarding the effects of testosterone therapy (TTh) on common disorders of the prostate. RECENT

findingsTestosterone therapy has gained credibility over the last several decades as a potentially safe co-treatment modality for men with benign and malignant prostatic conditions. Our understanding of the effects of testosterone on the prostate continues to evolve with ongoing clinical and basic science research. Findings of these studies have reinvigorated the debate over the effects of testosterone on benign and malignant disorders of the prostate, including BPH, chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and prostate cancer. SUMMARY: Despite the burgeoning body of data claiming the safety and efficacy of TTh in common prostatic conditions (including BPH, CP/CPPS, and prostate cancer), diligent monitoring, appropriate patient selection, and informed consent are critical until more definitive studies are performed.

Indexed as

Adultandrogen deprivationbenign prostatic hyperplasiachronic pelvic pain syndromechronic prostatitishumansprostate cancerprostate-specific antigen/serumQoLsex hormonestestosteronetreatmet outcome

Identifiers

PMID29056882
PMCPMC5648355
OpenAlexW2608439889

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.